Published in Blood Weekly, November 5th, 2009
The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China's blood products has soared up and corporate profitability also has increased significantly.
China's blood products industry has been in the transition of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.